FDA warned Clarke Pharmaceutical Manufacturing that it sells five unapproved drugs online, including a vitamin product claimed to prevent and treat COVID-19.
What happened
FDA reviewed the company's website www.clarkepharmaceuticals.com in December 2020 and January 2021 and also reviewed its YouTube videos, which direct viewers to the site to buy the products. FDA found the site takes orders for OsteoBLAST, Cell Block #19, High Potency Vitamin D3, Neupanex and Natural Progesterone Skin Cream using claims that they treat or prevent diseases such as osteoporosis, Alzheimer's, stroke, dementia, cancer and COVID-19. Because the products make these disease claims, FDA says they are unapproved new drugs and that their labels lack adequate directions for safe use by a layperson, making them misbranded.
What FDA found
The company sells products claiming to cure, treat, or prevent disease without the FDA approval required for a new drug.
Section 505(a) and 301(d) of the Act [21 U.S.C. 355(a), 331(d)]Cell Block #19 is promoted as protecting against, or treating, COVID-19 without FDA approval or authorization.
Section 505(a) of the Act [21 U.S.C. 355(a)]The products' labels do not give adequate directions for use, because the conditions they target cannot be safely self-treated without a licensed practitioner.
Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]The company moves misbranded drugs into interstate commerce.
Section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
FDA asks the company to take immediate action to stop selling unapproved products claimed to prevent, treat, diagnose, or cure COVID-19. Within 15 working days of receiving the letter, the company must write to FDA describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents; if it cannot finish in that time, it must explain the delay and give a completion date.
Who should pay attention
- supplement brands that publish disease or structure-function claims and patient testimonials on product pages
- online marketplaces and retailers listing supplements with COVID-19 or disease claims
- clinics and practitioners whose staff recommend or sell supplement protocols
This is a summary. Read the original letter on fda.gov.